World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
97
Citations
35315
World Ranking
9266
National Ranking
4784

Overview

Allan J. Pantuck is affiliated with the University of California, Los Angeles in the United States. Their research primarily focuses on medicine, biochemistry, genetics, and molecular biology, with significant contributions to pulmonary and respiratory medicine, molecular biology, oncology, surgery, and cancer research.

The scientist's work covers several main topics including:

  • Renal cell carcinoma treatment
  • Prostate cancer diagnosis and treatment
  • Renal and related cancers
  • Prostate cancer treatment and research
  • Bladder and urothelial cancer treatments
  • Cancer genomics and diagnostics
  • Cancer immunotherapy and biomarkers

Frequent publication venues where Allan J. Pantuck has contributed include:

  • The Journal of Urology
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Urologic Oncology Seminars and Original Investigations
  • The Lancet Oncology

Notable recent papers authored or coauthored by Allan J. Pantuck include:

  • A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer, 2020, Clinical Cancer Research
  • Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer, 2020, The Journal of Urology
  • MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study, 2022, The Lancet Oncology
  • [89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial, 2024, The Lancet Oncology
  • The Potential Revolution of Cancer Treatment with CRISPR Technology, 2023, Cancers

Allan J. Pantuck collaborates frequently with several coauthors, including:

  • Brian Shuch
  • Alexandra Drakaki
  • Laurence Klotz
  • Christian P. Pavlovich
  • Gencay Hatiboglu

Best Publications

  • Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina

  • THE CHANGING NATURAL HISTORY OF RENAL CELL CARCINOMA

    Allan J. Pantuck;Amnon Zisman;Arie S. Belldegrun

  • Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System

    Amnon Zisman;Allan J. Pantuck;Fredrick Dorey;Jonathan W. Said

  • Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience

    Jean Jacques Patard;Emmanuelle Leray;Nathalie Rioux-Leclercq;Luca Cindolo

  • Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma

    Amnon Zisman;Allan J. Pantuck;Jeffery Wieder;Debby H. Chao

  • Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy

    Matthew H.T. Bui;David Seligson;Ken ryu Han;Allan J. Pantuck

  • SAFETY AND EFFICACY OF PARTIAL NEPHRECTOMY FOR ALL T1 TUMORS BASED ON AN INTERNATIONAL MULTICENTER EXPERIENCE

    Jean-Jacques Patard;Oleg Shvarts;John S. Lam;Allan J. Pantuck

  • Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

    Alain Ravaud;Robert J. Motzer;Hardev S. Pandha;Daniel J. George

  • Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma

    Matthew H. T. Bui;David Seligson;Ken-ryu Han;Allan J. Pantuck

  • Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer

    Allan J. Pantuck;John T. Leppert;Nazy Zomorodian;William Aronson

  • Gene Signatures of Progression and Metastasis in Renal Cell Cancer

    Jon Jones;Hasan Otu;Dimitrios Spentzos;Shakirahmed Kolia

  • Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study

    Jean Jacques Patard;Hyung L. Kim;John S. Lam;Frederick J. Dorey

  • Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.

    Allan J. Pantuck;David B. Seligson;Tobias Klatte;Hong Yu

  • Pomegranate Ellagitannin-Derived Metabolites Inhibit Prostate Cancer Growth and Localize to the Mouse Prostate Gland

    Navindra P. Seeram;William J. Aronson;Yanjun Zhang;Susanne M. Henning

  • Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.

    Allan J. Pantuck;Amnon Zisman;Fredrick Dorey;Debby H. Chao

  • Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review

    Maxine Sun;Shahrokh F. Shariat;Christopher Cheng;Vincenzo Ficarra

  • Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT.

    Jonathan R. Young;Daniel Margolis;Steven Sauk;Allan J. Pantuck

  • Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery.

    Karim Bensalah;Allan J. Pantuck;Nathalie Rioux-Leclercq;Rodolphe Thuret

  • POSTOPERATIVE SURVEILLANCE PROTOCOL FOR PATIENTS WITH LOCALIZED AND LOCALLY ADVANCED RENAL CELL CARCINOMA BASED ON A VALIDATED PROGNOSTIC NOMOGRAM AND RISK GROUP STRATIFICATION SYSTEM

    John S. Lam;Oleg Shvarts;John T. Leppert;Allan J. Pantuck

  • Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience

    J.-J. Patard;E. Leray;N. Rioux-Leclercq;L. Cindolo

Frequent Co-Authors

Arie S. Belldegrun
Arie S. Belldegrun University of California, Los Angeles
Robert A. Figlin
Robert A. Figlin Cedars-Sinai Medical Center
Jonathan W. Said
Jonathan W. Said University of California, Los Angeles
Alexandre de la Taille
Alexandre de la Taille Université Paris Cité
Daniel J. George
Daniel J. George Duke University
Laurent Salomon
Laurent Salomon Necker-Enfants Malades Hospital
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Alain Ravaud
Alain Ravaud University of Bordeaux
Bernard Escudier
Bernard Escudier Institut Gustave Roussy
David Heber
David Heber University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine offers a wide range of alternative and complementary paths beyond MD or DO programs. Many students build foundational experience by studying through medical billing and coding schools with financial aid, providing quick entry into the healthcare administration field.

For those interested in patient care, nursing schools that don't require teas test create more accessible options to start a nursing degree, eliminating common exam-related barriers. Leadership roles within healthcare also continue to grow. Pursuing a healthcare administration degree can prepare you for administrative and managerial positions in various medical settings.

Additionally, nurses seeking further advancement may consider asn to np bridge programs that enable registered nurses to earn advanced degrees efficiently. These diverse pathways offer robust job prospects in healthcare, allowing for flexibility, career growth, and hands-on impact even if you do not pursue a traditional medical doctor degree.

Best Scientists Citing Allan J. Pantuck

Trending Scientists

Recently Published Articles